Journal Mobile Options
Table of Contents
Vol. 94, No. 3, 2011
Issue release date: November 2011
Neuroendocrinology 2011;94:246–254
(DOI:10.1159/000329391)

Bone Remodeling, Bone Mass and Weight Gain in Patients with Stabilized Schizophrenia in Real-Life Conditions Treated with Long-Acting Injectable Risperidone

Doknic M. · Maric N.P. · Britvic D. · Pekic S. · Damjanovic A. · Miljic D. · Stojanovic M. · Radojicic Z. · Jasovic Gasic M. · Popovic V.
aClinic for Endocrinology and bClinic for Psychiatry, Clinical Center of Serbia, cFaculty of Medicine and dFaculty of Organizational Sciences, University of Belgrade, Belgrade, Serbia

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Prolactin-raising antipsychotics, risperidone (antidopaminergic activity), may be associated with low bone mass. On the other hand, risperidone may cause an increase in body weight thought to be favorable for bone. Objectives: (1) To determine bone remodeling parameters and bone mass in patients with schizophrenia on long-term treatment with long-acting injectable risperidone (LAIR) in naturalistic settings, and (2) to evaluate the change in body weight, metabolic profile and neuroendocrine status in these patients. Design: This was a prospective, cross-sectional study. Patients: Patients included 26 outpatients with controlled schizophrenia in real-life conditions (age 31.3 ± 1.3 years, BMI 28.1 ± 1.0) on long-term maintenance therapy with LAIR for a mean of 18.0 ± 1.6 months (range 6–36) with a mean dose of 38 ± 2 mg. 35 subjects matched for sex, age, BMI and education served as healthy controls. Methods: Serum osteocalcin, C-terminal telopeptide of type I collagen (CTx), vitamin D, leptin, prolactin, sex steroids, and parathyroid hormone were assessed. Indices of insulin sensitivity and resistance were determined following an oral glucose tolerance test (OGTT). Bone mineral density (BMD) was measured by dual X-ray absorptiometry at the lumbar spine (LS) and femoral neck (FN). Results: Mild to moderate hyperprolactinemia (1,000–2,000 mU/l) was associated with asymptomatic hypogonadism. Prolactin values >2,000 mU/l occurred in a few female patients. Hypogonadism leads to a slight increase (upper limit of normal) in bone resorption marker (CTx) in patients with schizophrenia (p = 0.023). As for bone mass, although lower at the spine than in healthy subjects, it did not reach statistical significance (p = 0.094), while at the FN, BMD was not different from healthy subjects. Body weight increased on average 8.7 ± 1.6 kg in more than 50% of patients. Leptin levels adjusted for BMI in females were significantly higher in patients than in healthy female subjects (p = 0.018), while in males there was no difference between the groups (p = 0.833). A high prevalence of low vitamin D levels and more current smokers were found in patients with schizophrenia. As for the metabolic profile during treatment with risperidone, the low Matsuda index of insulin sensitivity (p = 0.039) confirmed insulin resistance in these patients. Conclusion: A potential long-term consequence of asymptomatic hypogonadism due to risperidone-induced hyperprolactinemia might cause a slight rise in bone resorption marker (CTx). On the other hand, by increasing body weight, risperidone could have a protective effect on the bone and thus no change in bone mass was recorded when compared with healthy controls.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Halbreich U: Osteoporosis, schizophrenia and antipsychotics. CNS Drugs 2007;21:641–657.
  2. O’Keane V, Meaney AM: Antipsychotic drug – a new risk factor for osteoporosis in young women with schizophrenia. J Clin Psychopharmacol 2005;25:26–31.
  3. Howard L, Kirkwood G, Leese M: Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007;190:129–134.
  4. Renn JH, Yang NP, Chueh CM, Lin CY, Lan TH, Chou P: Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord 2009;10:1.
  5. Takeda S, Karsenty G: Molecular bases of the sympathetic regulation of bone mass. Bone 2008;42:837–840.
  6. Yadav VK, Oury F, Suda N, Liu ZW, Gao XB, Confavreux C, Klemenhagen KC, Tanaka KF, Gingrich JA, Guo XE, Tecott LH, Mann JJ, Hen R, Horvath TL, Karsenty G: A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite and energy expenditure. Cell 2009;138:976–989.
  7. Karsenty G, Oury F: The central regulation of bone mass, the first link between bone remodeling and energy metabolism. J Clin Endocrinol Metab 2010;95:4795–4801.
  8. Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, Goltzman D, Canadian Multicentre Osteoporosis Study Research Group: Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007;167:188–194.
  9. Bishara D, Taylor D: Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008;68:2269–2292.
  10. Singh D, O’Connor DW: Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia. Clin Interv Aging 2009;4:351–355.
  11. Elefteriou F: Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys 2008;473:231–236.
  12. Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V: Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002;147:77–84.
  13. Ducy P, Schinke T, Karsenty G: The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000;289:1501–1504.
  14. Puntheerenurak S, Charoenphandhu N, Krishnamra N: Enhanced trabecular-bone calcium deposition in female rats with a high physiological dose of prolactin diminished after ovariectomy. Can J Physiol Pharmacol 2006;84:993–1002.
  15. Suntornsaratoon P, Wongdee K, Krishnamra N, Charoenphandhu N: Femoral bone mineral density and bone mineral content in bromocriptine-treated pregnant and lactating rats. J Physiol Sci 2010;60:1–8.
  16. Somma DC, Colao AM, Sarno DA, Klain M, Landi ML, Facciolli G, Pivonello R, Panza N, Salvatore M, Lombardi G: Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998;83:807–813.
  17. O’Keane V: Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008;22:70–75.
  18. Meaney AM, Smith S, Howes OD, O’Brien M, Murray RM, O’Keane V: Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004;184:503–508.
  19. Howard L, Kirkwood G, Leese M: Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007;190:129–134.
  20. Szarfman A, Tonning J, Levine J, Doraiswamy PM: Atypical antipsychotics and pituitary tumours: a pharmacovigilance study. Pharmacotherapy 2006;26:748–758.
  21. Tworoger S, Eliassen H, Sluss P, Hankinson S: A prospective study of plasma prolactin concentrations and the risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007;25:1147–1154.

    External Resources

  22. Llorca PM, Bouhours P, Moreau-Mallet V: Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone. Encephale 2008;34:170–178.
  23. Popovic V, Doknic M, Maric N, Pekic S, Damjanovic A, Miljic D, Popovic S, Miljic N, Djurovic M, Jasovic-Gasic M, Dieguez C, Casanueva FF: Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology 2007;85:249–256.
  24. Gentile S: Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes Rev 2009;10:527–542.
  25. Vidarsdottir S, Roelfsema F, Streefland T, Holst JJ, Rehfeld JF, Pijl H: Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. Eur J Endocrinol 2010;162:75–83.
  26. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197–207.
  27. Le Floh JP, Escuyer P, Baudin E, Baudon D, Perlemuter L: Blood glucose area under the curve. Methodological aspects. Diabetes Care 1990;13:172–175.
  28. Matthews JN, Altman DG, Campbell MJ, Royston P: Analysis of serial measurements in medical research. BMJ 1990;300:230–235.
  29. Matthews DR, Hosker JP, Rudneski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
  30. Hosker JP, Matthews DR, Rudneski AS, Burnett MA Darling P, Bown EG, Turner RC: Continuous infusion of glucose with model assessment: measurement of insulin resistance and β-cell function in man. Diabetologia 1985;28:401–411.
  31. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999;22:1462–1470.
  32. Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M: Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003;64:761–766.
  33. Meyer JM, Lehman D: Bone mineral density in male schizophrenia patients: a review. Ann Clin Psychiatry 2006;18:43–48.
  34. Meaney AM, O’Keane V: Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res 2007;93:136–143.
  35. Kishimoto T, Watanabe K, Shimada N, Makita K, Yagi G, Kashima H: Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry 2008;69:385–391.
  36. Naidoo U, Goff DC, Klibanski A: Hyperporlactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003;28:97–108.
  37. Montejo AL: Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharamacol 2008;18:S108–S114.
  38. Holt RIG, Peveler RC: Antipsychotics and hyperprolactinemia: mechanisms, consequences and management. Clin Endocrinol (Oxf) 2011;74:141–147.
  39. Seriwatanachai D, Thongchote K, Charoenphandhu N, Pandaranandaka J, Tudpor K, Teerapornpuntakit J, Suthiphongchai T, Krishnamra N: Prolactin directly enhances bone turnover by raising osteoblast-expressed receptors activator of nuclear factor-ĸB ligand/osteoprotegerin ratio. Bone 2008;42:535–546.
  40. Dick-de-Paula I, Welch G, Urs S, Kawai M, Maloney A, Bornstein S, Rosen CJ: Risperidone, a second-generation antipsychotic alters fat distribution and has a deleterious effect on bone mass in young C57BL6 males mice. ENDO 2010: The 92nd Annual Meeting & Expo, San Diego, Calif., USA, abstract book, P2–187.
  41. Hummer M, Malik P, Gasser R, Hofer A, Kemmler G, Naveda RCM, Rettenbacher M, Fleischhacker WW: Osteoporosis in patients with schizophrenia. Am J Psychiatry 2005;162:162–167.
  42. Bergeman N, Parzer P, Mund C, Auler B: High bone turnover but normal bone mineral density in women suffering from schizophrenia. Psychol Med 2008;38:1195–1202.
  43. Maric N, Popovic V, Jasovic-Gasic M, Pilipovic N, van Os J: Cumulative exposure to estrogen and psychosis: a peak bone mass, case-control study in first-episode psychosis. Schizophr Res 2005;73:351–355.
  44. Kishimoto T, Watanabe K, Takeuchi H, Kikuchi T, Nakajima S, Shimada N, Yagi G, Kashima H: Bone mineral density measurement in female inpatients with schizophrenia. Schizophr Res 2005;77:113–115.
  45. Lean M, De Smedt G: Schizophrenia and osteoporosis. Biol Psychiatry 2004;38:131–132.
  46. Haffner SM, Bauer RL: The association of obesity and glucose and insulin concentrations with bone density in premenopausal and postmenopausal women. Metabolism 1993;42:735–738.
  47. Fogelholm GM, Sievänen HT, Kukkonen-Harjula TK, Pasanen ME: Bone mineral density during reduction, maintenance and regain of body weight in premenopausal, obese women. Osteoporos Int 2001;12:199–206.
  48. McIntyre RS, Mancini DA, Basile VS: Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001;62:23–29.
  49. Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, Kodama M, Ishihara T, Kuroda S: Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry 2008;69:1416–1422.
  50. Zhang Z, Yao Z, Liu W, Fang Q, Reynolds G: Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Br J Psychiatry 2004;184:58–62.
  51. Popovic V, Duntas LH: Brain somatic cross-talk: ghrelin, leptin and ultimate challengers of obesity. Nutr Neurosci 2005;8:1–5.
  52. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R: Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137–141.
  53. Bergman RN, Ader M: Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005;66:504–514.
  54. Kim SH, Nikolics L, Abbasi F, Lamendola C, Link J, Reaven GM, Lindley S: Relationship between body mass index and insulin resistance in patients treated with second-generation antipsychotic agents. J Psychiatr Res 2010;44:493–498.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50